Persistent benefit of pharmacogenomic testing on initial remission and response rates in patients with major depressive disorder
Pharmacogenomic-guided treatment led to faster initial remission and response in patients with MDD, and this benefit persisted over 6 months with no evidence of changing over time.
Authors
- Alexander Gutin (ORCID: https://orcid.org/0000-0002-6565-3729)
- Andria L. Del Tredici (ORCID: https://orcid.org/0000-0002-9746-7728)
- Rebecca Law
- Kevin G. Lynch (ORCID: https://orcid.org/0000-0002-0426-0323)
- Daniel Hain (ORCID: https://orcid.org/0000-0001-6113-5521)
- David W. Oslin (ORCID: https://orcid.org/0000-0003-4392-4599)
- Brent Mabey
- Ryan Griggs
- Holly L. Johnson (ORCID: https://orcid.org/0000-0001-7080-5638)
- Katherine Johansen Taber
Institutions
- Philadelphia VA Medical Center (US)
- Myriad Genetics (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-10-30
- DOI
- https://doi.org/10.3389/fphar.2025.1658616
- Citations
- 1
- Primary Topic
- Treatment of Major Depression
- Type
- article
- Field-Weighted Citation Impact
- 1.39